Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00148083
Recruitment Status : Unknown
Verified August 2005 by University of Illinois at Chicago. Recruitment status was: Recruiting
The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit from skills training. The hypothesis guiding this study is that Risperdal Consta, by improving verbal memory, will improve the ability to benefit from skills training interventions among schizophrenia patients. The primary objective of this study is to compare patients on Risperdal Consta to patients on other atypical antipsychotic medications in terms of their ability to benefit from skills training interventions. A secondary objective of this study is to determine whether patients taking Risperdal Consta improve in other areas of cognitive functioning and social functioning.
Condition or disease
Drug: Risperdal Consta (drug)Behavioral: Social Skills Training
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 55 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Schizophrenia or schizoaffective disorder
Ability to give informed consent
Good general physical health or stable chronic medical conditions
Ability to be on a single antipsychotic medication
History of inattentiveness in psychosocial treatment settings
Poor social skills
Must be receiving a single antipsychotic medication
Must be clinically stable – defined by the absence of prominent delusions, hallucinations, disorganized speech, or grossly disorganized or catatonic behavior. However, there must also be continuing evidence of impairment, as indicated by the presence of negative symptoms or two or more symptoms of schizophrenia listed in Criterion A of the DSM-IV, in attenuated form (e.g., odd beliefs, unusual perceptual experiences).
Inability to give informed consent
Substance dependency in the past 6 months
Diagnosis of dementia
Significant head injury or other brain injury leading to cognitive impairment
Mental retardation (premorbid IQ < 65)
Pregnant or nursing
Allergy or other significant adverse reaction to risperidone
Contraindication to Risperdal Consta as only antipsychotic